| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
173,983,000 |
| Market
Cap: |
6.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.035 - $5.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates in the allergy, respiratory, and opioid overdose markets include: SYMJEPI™ (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis; ZIMHI™ (naloxone HCL Injection, USP) five mg/0.5 mL for the treatment of opioid overdose; and Tempol, an investigational drug. Co. also has a microbicide product candidate, named C31G.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Marguglio David J. |
Senior Vice President |
• • – |
2013-01-29 |
5 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
0 |
|
- |
|
| Marguglio David J. |
Senior Vice President |
• • – |
2013-01-04 |
5 |
GD |
$0.00 |
$0 |
I/I |
50,000 |
0 |
|
- |
|
| Carlo Dennis J Phd |
President & CEO |
• • – |
2011-12-29 |
5 |
GA |
$0.18 |
$18,000 |
I/I |
100,000 |
100,000 |
|
- |
|
| Carlo Dennis J Phd |
President & CEO |
• • – |
2011-12-29 |
5 |
GD |
$0.18 |
$36,000 |
D/D |
200,000 |
8,118,000 |
|
- |
|
| Daniels Karen K. |
Vice President of OperationsOf |
• – – |
2011-08-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,000 |
|
- |
|
| Moll Thomas |
Vice President of ResearchOffi |
• – – |
2011-08-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
279,000 |
|
- |
|
| Eses Holdings (fze) |
10% Owner |
– – • |
2011-06-30 |
4 |
A |
$0.25 |
$2,500,000 |
I/I |
10,000,000 |
30,000,000 |
|
- |
|
| Cohen Kenneth M |
Director |
– • – |
2011-01-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
50,000 |
|
- |
|
| Eses Holdings (fze) |
10% Owner |
– – • |
2010-11-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
20,000,000 |
|
- |
|
| Carlo Dennis J Phd |
President/CEOOfficer |
• • • |
2009-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,368,000 |
|
- |
|
| Aloi Richard L |
Director |
– • – |
2009-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,593,039 |
|
- |
|
| Marguglio David J. |
Director |
– • – |
2009-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,439,904 |
|
- |
|
| Hopkins Robert O |
Chief Financial OfficerOfficer |
• – – |
2009-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
870,750 |
|
- |
|
| Rothermel Robert B |
Director |
– • – |
2006-12-27 |
4 |
S |
$0.05 |
$1,100 |
D/D |
(20,000) |
0 |
|
- |
|
| Williams Richard C |
Director |
– • – |
2006-12-27 |
4 |
S |
$0.05 |
$540 |
D/D |
(10,000) |
20,000 |
|
- |
|
| Rothermel Robert B |
Director |
– • – |
2006-12-20 |
4 |
S |
$0.05 |
$825 |
D/D |
(15,000) |
20,000 |
|
- |
|
| Chandler John J |
VP, Corporate Development |
• – – |
2005-11-17 |
4 |
S |
$0.71 |
$3,550 |
D/D |
(5,000) |
10,000 |
|
- |
|
| Corner Anne-Marie |
Sr.VP, Womens Preventive |
• – – |
2005-05-26 |
4 |
OE |
$0.06 |
$617 |
D/D |
10,277 |
10,277 |
|
- |
|
| Rothermel Robert B |
Director |
– • – |
2005-05-12 |
4 |
B |
$2.13 |
$42,600 |
D/D |
20,000 |
35,000 |
2.39 |
- |
|
| Williams Richard C |
Interim CEO |
• • – |
2005-05-12 |
4 |
B |
$2.13 |
$42,600 |
D/D |
20,000 |
30,000 |
2.81 |
- |
|
| Sj Strategic Investments Llc |
10% Owner |
– – • |
2005-05-12 |
4 |
B |
$1.65 |
$371,250 |
I/I |
225,000 |
7,053,993 |
1.5 |
- |
|
| Tisch Thomas J |
10% Owner |
– – • |
2005-05-12 |
4 |
B |
$0.00 |
$0 |
I/I |
644,000 |
899,422 |
1.42 |
- |
|
| Adams John Q |
Director |
– • – |
2005-05-12 |
4 |
B |
$2.13 |
$21,300 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
| Karlin David A |
VP, Clinical Research |
• – – |
2004-12-29 |
4 |
S |
$2.73 |
$5,460 |
D/D |
(2,000) |
0 |
|
- |
|
| Chandler John J |
VP, Corporate Development |
• – – |
2004-12-27 |
4 |
S |
$2.63 |
$8,416 |
D/D |
(3,200) |
15,000 |
|
- |
|
212 Records found
|
|
Page 7 of 9 |
|
|
